These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16879778)

  • 1. Inhibition of the renin angiotensin system: implications for the endothelium.
    Savoia C; Schiffrin EL
    Curr Diab Rep; 2006 Aug; 6(4):274-8. PubMed ID: 16879778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial function and bradykinin in humans.
    Hornig B; Drexler H
    Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular renin-angiotensin-system, endothelial function and atherosclerosis?
    Holtz J; Goetz RM
    Basic Res Cardiol; 1994; 89 Suppl 1():71-86. PubMed ID: 7945178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
    Landmesser U; Drexler H
    J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
    Higashi Y; Chayama K; Yoshizumi M
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.
    Warnholtz A; Nickenig G; Schulz E; Macharzina R; Bräsen JH; Skatchkov M; Heitzer T; Stasch JP; Griendling KK; Harrison DG; Böhm M; Meinertz T; Münzel T
    Circulation; 1999 Apr; 99(15):2027-33. PubMed ID: 10209008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
    Mombouli JV; Vanhoutte PM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function.
    Zhang C; Hein TW; Wang W; Kuo L
    Circ Res; 2003 Feb; 92(3):322-9. PubMed ID: 12595345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological modulations of the renin-angiotensin-aldosterone system in human congestive heart failure: effects on peripheral vascular endothelial function.
    Nakamura M
    Curr Vasc Pharmacol; 2004 Jan; 2(1):65-70. PubMed ID: 15320834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade.
    Buczko W; Matys T; Kucharewicz I; Chabielska E
    J Physiol Pharmacol; 1999 Dec; 50(4):499-507. PubMed ID: 10639001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renin-angiotensin-aldosterone system: a specific target for hypertension management.
    Weir MR; Dzau VJ
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):205S-213S. PubMed ID: 10619573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inflammation and atherosclerosis: the role of Renin-Angiotensin system and its inhibition].
    Partigulova AS; Naumov VG
    Kardiologiia; 2010; 50(10):50-5. PubMed ID: 21118180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression.
    Olatunji LA; Seok YM; Igunnu A; Kang SH; Kim IK
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Nov; 389(11):1147-1157. PubMed ID: 27447455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelium and atherogenesis: endothelial therapy revisited.
    Barton M; Haudenschild CC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S23-5. PubMed ID: 11811371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins.
    Ko L; Maitland A; Fedak PW; Dumont AS; Badiwala M; Lovren F; Triggle CR; Anderson TJ; Rao V; Verma S
    Ann Thorac Surg; 2002 Apr; 73(4):1185-8. PubMed ID: 11996261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.